Sergei Dmitruk, MD
Ophthalmology · Louisville, KYNPI 1184158602
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,790 of the $5,198 with a category attached, or 72.9%. 21 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 34.1% of the total. Reporting peaked in 2019 at $1,876 and has fallen 64.9% since, to $659 in 2025.
Across 134 payments — averaging $38.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Alcon$2K
- AbbVie$436
- Johnson & Johnson Surgical Vision, Inc.$328
- Biotissue Holdings Inc.$144
- Sight Sciences, Inc.$139
- plus $623 from 15 others
What the payments were for
- Travel & lodging$1,32625%
- Food & beverage$3,79073%
- Education$832%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $1,770 |
| Alcon | 76 | $1,758 |
| AbbVie(2 entities) | 12 | $436 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $328 |
| Biotissue Holdings Inc. | 3 | $144 |
| Sight Sciences, Inc. | 2 | $139 |
| Aerie Pharmaceuticals, Inc. | 2 | $127 |
| Regeneron Healthcare Solutions, Inc. | 2 | $102 |
| Rxsight Inc | 2 | $93 |
| ANI Pharmaceuticals, Inc. | 2 | $51 |
| Bausch & Lomb Americas Inc. | 2 | $41 |
| Tarsus Pharmaceuticals, Inc. | 1 | $32 |
| Glaukos Corporation | 1 | $30 |
| Astellas Pharma US Inc | 1 | $22 |
| Rayner Intraocular Lenses Limited | 1 | $22 |
| Alimera Sciences, Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Amgen | 1 | $19 |
| Dompe US, Inc. | 1 | $18 |
| Spark Therapeutics, Inc. | 1 | $13 |
| NEW World Medical,inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPHTHALMIC INSTRUMENTS$1,301
- TRULIGN TORIC$1,301
- ENVISTA$1,301
- CRYSTALENS$1,301
- Tecnis IOL$399
- Hydrus Microstent$237
- Clareon PanOptix Pro$125
- Rhopressa$123
- XEN GLAUCOMA TREATMENT SYSTEM$120
- Prokera$119
- AmnioGraft$119
- OMNI(R) SURGICAL SYSTEM (US)$118
- Clareon$109
- AcrySof IQ PanOptix UV IOL$108
- AcrySof IQ VIVITY$108
How this compares
$5,198 in reported general payments places this provider in the 80th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 13 | $9,470 |
| LumiganBimatoprost | 12 | $5,866 |
| Prednisolone Acetate | 78 | $3,099 |
| Travoprost | 11 | $1,128 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 48 | $1,084 |
| Brimonidine Tartrate | 16 | $1,049 |
| Latanoprost | 102 | $661 |
| MoxifloxacinMoxifloxacin Hcl | 24 | $616 |
| Doxycycline Monohydrate | 13 | $430 |
| ErythromycinErythromycin Base | 41 | $418 |
| Timolol Maleate | 39 | $339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $436 | $15,33625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in Louisville
- Jeremy ClarkLouisville$131K
- Guruprasad PattarLouisville$36K
- Gary FoulksLouisville$16K
- Christopher ComptonLouisville$13K
- Inder SingalLouisville$9K
- Rishi KumarLouisville$8K
- Frank BurnsLouisville$8K
- Steven BloomLouisville$6K
- Sharmini BalakrishnanLouisville$6K
- Lawrence TenkmanLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.